Abstract 289MO
Background
Fruquintinib (F, a highly selective VEGFR inhibitor) plus sintilimab (S, an anti-PD-1 monoclonal antibody) showed promising antitumor activity in both pre-clinical and clinical studies. Here, we reported the results of F plus S from CC cohort in an open-label, multicenter, single-arm phase 2 study.
Methods
Pts with pathologically confirmed advanced CC who had failed at least first-line platinum-containing treatment, or experienced intolerable toxicity during treatment, or were unable to receive standard therapy were eligible. Eligible pts received F (5 mg, 2 weeks [wk] on/1 wk off, orally, once daily) plus S (200 mg, IV, every 3 wk) in 21-day cycles, until disease progression or unacceptable toxicity. Treatment of S was allowed for up to 24 months (mo). The primary endpoint was ORR per RECIST v1.1.
Results
As of May 30, 2023, 34 pts were successfully enrolled and received F plus S, median follow-up duration was 16.4 mo. Median (range) age was 56 (26.2, 73.7) yrs. 6 pts (17.6%) were treatment naïve (naïve pts); 28 pts (82.4%) had received at least first-line treatment (treated pts), including bevacizumab (5/28), for advanced disease. 25 pts (73.5%) had received pelvic radiation therapy. There were 24 pts (70.6%) with PD-L1 status of CPS ≥1. Among tumor evaluable naïve and treated pts, confirmed ORR (cORR) were 50.0% (PR 3/6) and 29.6% (CR 1/27 and PR 7/27); median TTR were 2.7 and 3.1 mo; DCR were both 100%. In naïve (N=6) and treated (N=28) pts, mPFS were 10.3 and 8.2 mo, 15mo-OS rate were 83.3% and 70.0%. In tumor evaluable treated pts stratified by CPS ≥1 vs <1 (N= 17 vs 8), cORR was 41.2% vs 12.5%; in treated pts (N=18 vs 8), mPFS was 19.4 vs 5.2 mo; mOS was not reached vs 13.9 mo, 15mo-OS rate was 76.0% vs 50.0%. All pts experienced TEAEs, and the most common TEAEs included proteinuria (64.7%), hypothyroidism (61.8%), asthenia (44.1%), hyperthyroidism (44.1%), palmar-plantar erythrodysaesthesia syndrome (44.1%), anaemia (41.2%) and urinary tract infection (41.2%).
Conclusions
F plus S provided favorable efficacy in advanced CC pts, especially for treated PD-L1 CPS ≥1 pts. This combination treatment also showed manageable toxicity profile consistent with that seen in other cohorts.
Clinical trial identification
NCT03903705.
Editorial acknowledgement
Legal entity responsible for the study
HUTCHMED Limited.
Funding
HUTCHMED Limited.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
285O - Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study
Presenter: Svetlana Khokhlova
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
286MO - Efficacy of low dose nivolumab in recurrent / metastatic cervical cancer
Presenter: Sowmica Devabhaktuni
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
287MO - Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive
Presenter: Somnath Roy
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 285O, 286MO and 287MO
Presenter: Smruti Koppikar
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Webcast
288MO - InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
290MO - Efficacy and safety of topical sintilimab administration in conjunction with CRT and Californium-252 neutron brachytherapy in first-line advanced gynecological squamous cell carcinoma patients
Presenter: Xiaoling Li
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 288MO, 289MO and 290MO
Presenter: Alexandra Leary
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Webcast
LBA8 - Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Presenter: Natalie Ngoi
Session: Mixed Proffered paper and Mini oral session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast